Zebrafish as a Versatile Model Organism: From Tanks to Treatment

Abstract

Zebrafish (Danio rerio) have gained prominence as a model organism in biomedical research due to its genetic accessibility, optical transparency during embryonic development, and physiological similarities to humans. These traits make zebrafish ideal for studying various human diseases, though broader insights into their diverse applications are still needed. This review explores zebrafish as a versatile model for studying both communicable and non-communicable diseases. In communicable diseases, it has become a powerful model for studying host–pathogen interactions, immune responses, and therapeutic screening, with its transparency enabling real-time tracking of infections. Robust models also exist for many bacterial, viral, and fungal pathogens, supported by early innate immune cell development. Additionally, microinjection techniques enable precise local or systemic infections, making zebrafish a versatile, high-resolution model for studying disease mechanisms. For non-communicable diseases, zebrafish support research on cardiovascular, metabolic, neurodegenerative disorders, and cancer. This review highlights recent advances in using zebrafish to study disease mechanisms, drug discovery, and therapies. It underscores the academic and translational value of zebrafish, promoting innovative strategies to improve human health outcomes. Their versatility across disciplines makes them an effective tool for both fundamental research and biomedical education, positioning them as a bridge between basic science and clinical applications.

Keywords

communicable disease / immune responses / non-communicable disease / translational research / zebrafish

References

[1] T. Teame, Z. Zhang, C. Ran, et al., “The Use of Zebrafish (Danio rerio) as Biomedical Models,” Animal Frontiers 9 (2019): 68–77.

[2] A. V. Kalueff, A. M. Stewart, and R. Gerlai, “Zebrafish as an Emerging Model for Studying Complex Brain Disorders,” Trends in Pharmacological Sciences 35 (2014): 63–75.

[3] R. Mrinalini, T. Tamilanban, V. Naveen Kumar, and K. Manasa, “Zebrafish—The Neurobehavioural Model in Trend,” Neuroscience 520 (2023): 95–118.

[4] S. Cassar, I. Adatto, J. L. Freeman, et al., “Use of Zebrafish in Drug Discovery Toxicology,” Chemical Research in Toxicology 33 (2020): 95–118.

[5] M. K. Gautam, P. K. Panda, A. Dubey, M. Kumari, and N. S. Ghosh, “Zebrafish as a Fascinating Animal Model: A Robust Platform for in Vivo Screening for Biomedical Research,” International Journal of Pharmaceutical Investigation 14 (2024): 696–701.

[6] S. Brugman, “The Zebrafish as a Model to Study Intestinal Inflammation,” Developmental & Comparative Immunology 64 (2016): 82–92.

[7] K. Howe, M. D. Clark, C. F. Torroja, et al., “The Zebrafish Reference Genome Sequence and Its Relationship to the Human Genome,” Nature 496 (2013): 498–503.

[8] G. Kari, U. Rodeck, and A. P. Dicker, “Zebrafish: An Emerging Model System for Human Disease and Drug Discovery,” Clinical Pharmacology & Therapeutics 82 (2007): 70–80.

[9] W. Y. Hwang, Y. Fu, D. Reyon, et al., “Efficient Genome Editing in Zebrafish Using a CRISPR-Cas System,” Nature Biotechnology 31 (2013): 227–229.

[10] T. Bondue, S. P. Berlingerio, L. van den Heuvel, and E. Levtchenko, “The Zebrafish Embryo as a Model Organism for Testing mRNA-Based Therapeutics,” International Journal of Molecular Sciences 24 (2023): 11224.

[11] D. Y. R. Stainier, E. Raz, N. D. Lawson, et al., “Guidelines for Morpholino Use in Zebrafish,” PLOS Genetics 13 (2017): e1007000.

[12] C. A. MacRae and R. T. Peterson, “Zebrafish as Tools for Drug Discovery,” Nature Reviews Drug Discovery 14 (2015): 721–731.

[13] J. M. González-Rosa, “Zebrafish Models of Cardiac Disease: From Fortuitous Mutants to Precision Medicine,” Circulation Research 130 (2022): 1803–1826.

[14] C. Sullivan and C. H. Kim, “Zebrafish as a Model for Infectious Disease and Immune Function,” Fish & Shellfish Immunology 25 (2008): 341–350.

[15] M. C. Gomes and S. Mostowy, “The Case for Modeling Human Infection in Zebrafish,” Trends in Microbiology 28 (2020): 10–18.

[16] P. Herbomel, “Spinning Nuclei in the Brain of the Zebrafish Embryo,” Current Biology 9 (1999): R627–R628.

[17] D. Le Guyader, M. J. Redd, E. Colucci-Guyon, et al., “Origins and Unconventional Behavior of Neutrophils in Developing Zebrafish,” Blood 111 (2008): 132–141.

[18] F. Basheer, C. Liongue, and A. Ward, “Zebrafish Bacterial Infection Assay to Study Host-Pathogen Interactions,” BIO-PROTOCOL 10 (2020): e3536.

[19] V. Torraca and S. Mostowy, “Zebrafish Infection: From Pathogenesis to Cell Biology,” Trends in Cell Biology 28 (2018): 143–156.

[20] G. M. Duggan and S. Mostowy, “Use of Zebrafish to Study Shigella Infection,” Disease Models & Mechanisms 11 (2018): dmm032151.

[21] S. A. Renshaw and N. S. Trede, “A Model 450 Million Years in the Making: Zebrafish and Vertebrate Immunity,” Disease Models & Mechanisms 5 (2012): 38–47.

[22] J. Galindo-Villegas, D. García-Moreno, S. de Oliveira, J. Meseguer, and V. Mulero, “Regulation of Immunity and Disease Resistance by Commensal Microbes and Chromatin Modifications During Zebrafish Development,” Proceedings of the National Academy of Sciences of the United States of America 109 (2012): E2605–E2614.

[23] Y. Li, Y. Li, X. Cao, X. Jin, and T. Jin, “Pattern Recognition Receptors in Zebrafish Provide Functional and Evolutionary Insight Into Innate Immune Signaling Pathways,” Cellular & Molecular Immunology 14 (2017): 80–89.

[24] A. Kumar and H. Schweizer, “Bacterial Resistance to Antibiotics: Active Efflux and Reduced Uptake,” Advanced Drug Delivery Reviews 57 (2005): 1486–1513.

[25] K. Z. Miao, G. Y. Kim, G. K. Meara, X. Qin, and H. Feng, “Tipping the Scales With Zebrafish to Understand Adaptive Tumor Immunity,” Frontiers in Cell and Developmental Biology 9 (2021): 660969.

[26] C. Medina and J. L. Royo, “Zebrafish as a Model Organism to Study Host–Pathogen Interactions,” Methods 62 (2013): 241–245.

[27] X. Zhang, Y. Zhao, Q. Wu, et al., “Zebrafish and Galleria mellonella: Models to Identify the Subsequent Infection and Evaluate the Immunological Differences in Different Klebsiella pneumoniae Intestinal Colonization Strains,” Frontiers in Microbiology 10 (2019): 2750.

[28] S. Mostowy, L. Boucontet, M. J. Mazon Moya, et al., “The Zebrafish as a New Model for the In Vivo Study of Shigella flexneri Interaction With Phagocytes and Bacterial Autophagy,” PLoS Pathogens 9 (2013): e1003588.

[29] S. Pont and A.-B. Blanc-Potard, “Zebrafish Embryo Infection Model to Investigate Pseudomonas aeruginosa Interaction With Innate Immunity and Validate New Therapeutics,” Frontiers in Cellular and Infection Microbiology 11 (2021): 745851.

[30] P. Nogaret, F. El Garah, and A.-B. Blanc-Potard, “A Novel Infection Protocol in Zebrafish Embryo to Assess Pseudomonas aeruginosa Virulence and Validate Efficacy of a Quorum Sensing Inhibitor In Vivo,” Pathogens 10 (2021): 401.

[31] E. E. Rosowski, B. P. Knox, L. S. Archambault, et al., “The Zebrafish as a Model Host for Invasive Fungal Infections,” Journal of Fungi 4 (2018): 136.

[32] A. López-Muñoz, F. E. Nicolás, D. García-Moreno, et al., “An Adult Zebrafish Model Reveals That Mucormycosis Induces Apoptosis of Infected Macrophages,” Scientific Reports 8 (2018): 12802.

[33] B. E. V. Koch, N. H. Hajdamowicz, E. Lagendijk, A. F. J. Ram, and A. H. Meijer, “Aspergillus fumigatus Establishes Infection in Zebrafish by Germination of Phagocytized Conidia, While Aspergillus niger Relies on Extracellular Germination,” Scientific Reports 9 (2019): 12791.

[34] K. M. Brothers, Z. R. Newman, and R. T. Wheeler, “Live Imaging of Disseminated Candidiasis in Zebrafish Reveals Role of Phagocyte Oxidase in Limiting Filamentous Growth,” Eukaryotic Cell 10 (2011): 932–944.

[35] C.-C. Chao, P. C. Hsu, C. F. Jen, et al., “Zebrafish as a Model Host for Candida albicans Infection,” Infection and Immunity 78 (2010): 2512–2521.

[36] G. Forn-Cuní, L. Welvaarts, F. Stel, et al., “Stimulating the Autophagic-Lysosomal Axis Enhances Host Defense Against Fungal Infection in a Zebrafish Model of Invasive Aspergillosis,” Autophagy 19 (2023): 324–337.

[37] C. Sullivan, B.-L. Soos, P. J. Millard, C. H. Kim, and B. L. King, “Modeling Virus-Induced Inflammation in Zebrafish: A Balance Between Infection Control and Excessive Inflammation,” Frontiers in Immunology 12 (2021): 636623.

[38] E. Habjan, V. Q. T. Ho, J. Gallant, et al., “An Anti-Tuberculosis Compound Screen Using a Zebrafish Infection Model Identifies an Aspartyl-tRNA Synthetase Inhibitor,” Disease Models & Mechanisms 14 (2021): dmm049145.

[39] J. P. Sridevi, H. S. Anantaraju, P. Kulkarni, P. Yogeeswari, and D. Sriram, “Optimization and Validation of Mycobacterium marinum-Induced Adult Zebrafish Model for Evaluation of Oral Anti-Tuberculosis Drugs,” International Journal of Mycobacteriology 3 (2014): 259–267.

[40] N. L. Stevanović, B. Đ. Glišić, S. Vojnovic, et al., “Improvement of the Anti-Candida Activity of Itraconazole in the Zebrafish Infection Model by Its Coordination to Silver(I),” Journal of Molecular Structure 1232 (2021): 130006.

[41] P. Hauswirth, J. Buck, R. Puligilla, et al., “Zebrafish Larvae as an in Vivo Model for Antimicrobial Activity Tests Against Intracellular Salmonella,” Frontiers in Bioscience-Landmark 28 (2023): 99.

[42] J. P. Dalton, B. Uy, K. S. Okuda, et al., “Screening of Anti-Mycobacterial Compounds in a Naturally Infected Zebrafish Larvae Model,” Journal of Antimicrobial Chemotherapy 72 (2017): 421–427.

[43] J. S. Burgos, J. Ripoll-Gomez, J. M. Alfaro, I. Sastre, and F. Valdivieso, “Zebrafish as a New Model for Herpes Simplex Virus Type 1 Infection,” Zebrafish 5 (2008): 323–333.

[44] K. A. Gabor, et al., “Influenza A Virus Infection in Zebrafish Recapitulates Mammalian Infection and Sensitivity to Anti-Influenza Drug Treatment,” Disease Models & Mechanisms 7 (2014): 1227–1237.

[45] M. Varela, A. Figueras, and B. Novoa, “Modelling Viral Infections Using Zebrafish: Innate Immune Response and Antiviral Research,” Antiviral Research 139 (2017): 59–68.

[46] I. Cox and R. Crook, The Pathology and Pathophysiology of Coronary Artery Disease (Springer Nature, 1996), 121–138, https://doi.org/10.1007/978-94-011-5406-2_11.

[47] H. F. Weisman and B. H. Bulkley, “Pathophysiology of Atherosclerotic Heart Disease,” Cardiology Clinics 2 (1984): 555–569.

[48] D. M. Davidson, “An Introduction to Cardiovascular Disease,” Social Support and Cardiovascular Disease (1994): 3–19, https://doi.org/10.1007/978-1-4899-2572-5_1.

[49] M. J. S. Zaman, E. J. Brunner, and H. Hemingway, “Cardiovascular Disease: Overview and Trends,” International Encyclopedia of Public Health 451 (2008): 511–538, https://doi.org/10.1016/B978-012373960-5.00003-4.

[50] L. Zang, V. Torraca, Y. Shimada, and N. Nishimura, “Editorial: Zebrafish Models for Human Disease Studies,” Frontiers in Cell and Developmental Biology 10 (2022): 861941.

[51] A. Coppola, P. Lombari, E. Mazzella, et al., “Zebrafish as a Model of Cardiac Pathology and Toxicity: Spotlight on Uremic Toxins,” International Journal of Molecular Sciences 24 (2023): 5656.

[52] R. S. Angom and N. M. R. Nakka, “Zebrafish as a Model for Cardiovascular and Metabolic Disease: The Future of Precision Medicine,” Biomedicines 12 (2024): 693.

[53] Y. Niu, Y. Sun, Y. Liu, K. Du, X. Xu, and Y. Ding, “Using Zebrafish Animal Model to Study the Genetic Underpinning and Mechanism of Arrhythmogenic Cardiomyopathy,” International Journal of Molecular Sciences 24 (2023): 4106.

[54] R. E. Quick, L. D. Buck, S. Parab, Z. R. Tolbert, and R. L. Matsuoka, “Highly Efficient Synthetic CRISPR RNA/Cas9-Based Mutagenesis for Rapid Cardiovascular Phenotypic Screening in F0 Zebrafish,” Frontiers in Cell and Developmental Biology 9 (2021): 735598.

[55] H. Sree Kumar, A. S. Wisner, J. M. Refsnider, C. J. Martyniuk, and J. Zubcevic, “Small Fish, Big Discoveries: Zebrafish Shed Light on Microbial Biomarkers for Neuro-Immune-Cardiovascular Health,” Frontiers in Physiology 14 (2023): 1186645.

[56] G. Bowley, E. Kugler, R. Wilkinson, et al., “Zebrafish as a Tractable Model of Human Cardiovascular Disease,” British Journal of Pharmacology 179 (2022): 900–917.

[57] M. Van Impe, L. Caboor, V. Deleeuw, et al., “Fluid-Structure Interaction Modeling of the Aortic Hemodynamics in Adult Zebrafish: A Pilot Study Based on Synchrotron X-Ray Tomography,” IEEE Transactions on Biomedical Engineering 70 (2023): 2101–2110.

[58] M. Adhish and I. Manjubala, “Effectiveness of Zebrafish Models in Understanding Human Diseases—A Review of Models,” Heliyon 9 (2023): e14557.

[59] B. Joshi, G. Wagh, H. Kaur, and C. Patra, “Zebrafish Model to Study Angiotensin II-Mediated Pathophysiology,” Biology 10 (2021): 1177.

[60] C. G. Sobey, et al., “How Good Are Our Models of Cardiovascular Disease? Introducing Our Themed Issue on Preclinical Models for Cardiovascular Disease Research,” British Journal of Pharmacology 179 (2022), https://doi.org/10.1111/BPH.15798.

[61] M. Maciag, A. Wnorowski, M. Mierzejewska, and A. Plazinska, “Pharmacological Assessment of Zebrafish-Based Cardiotoxicity Models,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 148 (2022): 112695.

[62] S. K. Rajpurohit, A. Gopal, M. Y. Mon, N. G. Patel, and V. Arora, “Development of Tg(UAS:SEC-Hsa.ANXA5-YFP,myl7:RFP); Casper(roy−/−,nacre−/−) Transparent Transgenic In Vivo Zebrafish Model to Study the Cardiomyocyte Function,” Cells 10 (2021): 1963.

[63] S. K. Rajpurohit, L. Ouellette, S. Sura, et al., “Development of a Transparent Transgenic Zebrafish Cellular Phenotype Tg(6xNF-kB:EGFP); Casper(roy−/−, nacre−/−) to Study NF-kB Activity,” Biomedicines 11 (2023): 1985.

[64] R. N. Wilkinson, C. Jopling, and F. J. M. Van Eeden, “Zebrafish as a Model of Cardiac Disease,” Progress in Molecular Biology and Translational Science 124 (2014): 65–91.

[65] M. Vasyutina, A. Alieva, O. Reutova, et al., “The Zebrafish Model System for Dyslipidemia and Atherosclerosis Research: Focus on Environmental/Exposome Factors and Genetic Mechanisms,” Metabolism 129 (2022): 155138.

[66] D. Tang, F. Geng, C. Yu, and R. Zhang, “Recent Application of Zebrafish Models In Atherosclerosis Research,” Frontiers in Cell and Developmental Biology 9 (2021): 643697.

[67] M. G. Saklayen, “The Global Epidemic of the Metabolic Syndrome,” Current Hypertension Reports 20 (2018): 12.

[68] M. H. C. Gurgel, R. M. Montenegro Junior, C. M. Melo Ponte, et al., “Metabolic Syndrome, Diabetes and Inadequate Lifestyle in First-Degree Relatives of Acute Myocardial Infarction Survivors Younger Than 45 Years Old,” Lipids in Health and Disease 16 (2017): 224.

[69] M. Kleinert, C. Clemmensen, S. M. Hofmann, et al., “Animal Models of Obesity and Diabetes Mellitus,” Nature Reviews Endocrinology 14 (2018): 140–162.

[70] B. Ghaddar, B. Veeren, P. Rondeau, et al., “Impaired Brain Homeostasis and Neurogenesis in Diet-Induced Overweight Zebrafish: A Preventive Role From A. borbonica extract,” Scientific Reports 10 (2020): 14496.

[71] V. E. Prince, R. M. Anderson, and G. Dalgin, “Zebrafish Pancreas Development and Regeneration: Fishing for Diabetes Therapies,” Curr Top Dev Biol 124 (2017): 235–276.

[72] M. Hölttä-Vuori, V. T. V. Salo, L. Nyberg, et al., “Zebrafish: Gaining Popularity in Lipid Research,” Biochemical Journal 429 (2010): 235–242.

[73] L. Zang, L. A. Maddison, and W. Chen, “Zebrafish as a Model for Obesity and Diabetes,” Frontiers in Cell and Developmental Biology 6 (2018): 91.

[74] E.-A. Kim, S. H. Lee, J. H. Lee, et al., “Correction: A Marine Algal Polyphenol, Dieckol, Attenuates Blood Glucose Levels by Akt Pathway in Alloxan Induced Hyperglycemia Zebrafish Model,” RSC Advances 6 (2016): 83563.

[75] M. Caro, I. Iturria, M. Martinez-Santos, et al., “Zebrafish Dives Into Food Research: Effectiveness Assessment of Bioactive Compounds,” Food & Function 7 (2016): 2615–2623.

[76] X. Li, G. Ge, G. Song, Q. Li, and Z. Cui, “Effects of Nutritionally Induced Obesity on Metabolic Pathways of Zebrafish,” International Journal of Molecular Sciences 24 (2023): 1850.

[77] X. Peng, G. Shang, W. Wang, et al., “Fatty Acid Oxidation in Zebrafish Adipose Tissue Is Promoted by 1α,25(OH)2D3,” Cell Reports 19 (2017): 1444–1455.

[78] M. Michel, P. S. Page-McCaw, W. Chen, and R. D. Cone, “Leptin Signaling Regulates Glucose Homeostasis, But Not Adipostasis, in the Zebrafish,” Proceedings of the National Academy of Sciences of the United States of America 113 (2016): 3084–3089.

[79] A. Schlegel and D. Y. R. Stainier, “Microsomal Triglyceride Transfer Protein Is Required for Yolk Lipid Utilization and Absorption of Dietary Lipids in Zebrafish Larvae,” Biochemistry 45 (2006): 15179–15187.

[80] E. J. Flynn, C. M. Trent, and J. F. Rawls, “Ontogeny and Nutritional Control of Adipogenesis in Zebrafish (Danio rerio),” Journal of Lipid Research 50 (2009): 1641–1652.

[81] K. Landgraf, S. Schuster, A. Meusel, et al., “Short-Term Overfeeding of Zebrafish With Normal or High-Fat Diet as a Model for the Development of Metabolically Healthy Versus Unhealthy Obesity,” BMC Physiology 17 (2017): 4.

[82] L. Zang, Y. Shimada, and N. Nishimura, “Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus,” Scientific Reports 2017 7:1 7 (2017): 1–11.

[83] L. Fang, C. Liu, and Y. I. Miller, “Zebrafish Models of Dyslipidemia: Relevance to Atherosclerosis and Angiogenesis,” Translational Research 163 (2014): 99–108.

[84] P. J. Babin, C. Thisse, M. Durliat, M. Andre, M. A. Akimenko, and B. Thisse, “Both Apolipoprotein E and A-I Genes Are Present in a Nonmammalian Vertebrate and Are Highly Expressed During Embryonic Development,” Proceedings of the National Academy of Sciences of the United States of America 94 (1997): 8622–8627.

[85] P. J. Babin, “Plasma Lipoprotein and Apolipoprotein Distribution as a Function of Density in the Rainbow Trout (Salmo gairdneri),” Biochemical Journal 246 (1987): 425–429.

[86] K. Stoletov, L. Fang, S. H. Choi, et al., “Vascular Lipid Accumulation, Lipoprotein Oxidation, and Macrophage Lipid Uptake in Hypercholesterolemic Zebrafish,” Circulation Research 104 (2009): 952–960.

[87] S. Tsimikas, E. S. Brilakis, E. R. Miller, et al., “Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease,” New England Journal of Medicine 353 (2005): 46–57.

[88] T. O. Auer, K. Duroure, A. De Cian, J. P. Concordet, and F. Del Bene, “Highly Efficient CRISPR/Cas9-Mediated Knock-In in Zebrafish by Homology-Independent DNA Repair,” Genome Research 24 (2014): 142–153.

[89] J. Huisken and D. Y. R. Stainier, “Selective Plane Illumination Microscopy Techniques in Developmental Biology,” Development 136 (2009): 1963–1975.

[90] J. Moosmann, A. Ershov, V. Altapova, et al., “X-Ray Phase-Contrast In Vivo Microtomography Probes New Aspects of Xenopus Gastrulation,” Nature 497 (2013): 374–377.

[91] B. D. Fontana, N. J. Mezzomo, A. V. Kalueff, and D. B. Rosemberg, “The Developing Utility of Zebrafish Models of Neurological and Neuropsychiatric Disorders: A Critical Review,” Experimental Neurology 299 (2018): 157–171.

[92] D. J. Surmeier and D. Sulzer, “The Pathology Roadmap in Parkinson Disease,” Prion 7 (2013): 85–91.

[93] F. Blandini and M. T. Armentero, “Animal Models of Parkinson's Disease,” FEBS Journal 279 (2012): 1156–1166.

[94] P. Gubellini and P. Kachidian, “Animal Models of Parkinson's Disease: An Updated Overview,” Revue Neurologique 171 (2015): 750–761.

[95] M. P. McDonald, “Methods and Models of the Nonmotor Symptoms of Parkinson Disease,” in Movement Disorders: Genetics and Models, Clinical Neurology, 2nd ed. (2015), 387–412, https://doi.org/10.1016/B978-0-12-405195-9.00023-8.

[96] E. C. Hirsch, “Animal Models in Neurodegenerative Diseases,” Journal of Neural Transmission, Supplementa 72 (2007): 87–90, https://doi.org/10.1007/978-3-211-73574-9_11.

[97] R. Betarbet and J. T. Greenamyre, “Parkinson's Disease: Animal Models,” Handbook of Clinical Neurology 83 (2007): 265–287.

[98] K. E. Soderstrom, G. Baum, and J. H. Kordower, “Animal Models of Parkinson's Disease,” Encyclopedia of Neuroscience 1 (A–C) (2009): 455–463, https://doi.org/10.1016/B978-008045046-9.00522-2.

[99] W. Dauer, “Overview: Rodent and Fish Models of Parkinson's Disease,” Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems 269 (2008): 219–223, https://doi.org/10.1016/B978-0-12-374028-1.00016-6.

[100] S. Guo, “Insights From Zebrafish PD Models and Their Potentials for Identifying Novel Drug Targets and Therapeutic Compounds,” in Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems (2008), 309–319, https://doi.org/10.1016/B978-0-12-374028-1.00023-3.

[101] T. C. Farrell, C. L. Cario, C. Milanese, A. Vogt, J. H. Jeong, and E. A. Burton, “Evaluation of Spontaneous Propulsive Movement as a Screening Tool to Detect Rescue of Parkinsonism Phenotypes in Zebrafish Models,” Neurobiology of Disease 44 (2011): 9–18.

[102] O. Wasel and J. L. Freeman, “Chemical and Genetic Zebrafish Models to Define Mechanisms of and Treatments for Dopaminergic Neurodegeneration,” International Journal of Molecular Sciences 21 (2020): 5981.

[103] M. Kalyn, K. Hua, S. Mohd Noor, C. E. D. Wong, and M. Ekker, “Comprehensive Analysis of Neurotoxin-Induced Ablation of Dopaminergic Neurons in Zebrafish Larvae,” Biomedicines 8 (2020): 1.

[104] Y. Vijayanathan, F. T. Lim, S. M. Lim, et al., “6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinson's Disease Model for Dopaminergic Neuroregeneration,” Neurotoxicity Research 32 (2017): 496–508.

[105] E. Bagwell, M. Shin, N. Henkel, D. Migliaccio, C. Peng, and J. Larsen, “1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Treated Adult Zebrafish as a Model for Parkinson's Disease,” Neuroscience Letters 842 (2024): 137991.

[106] A. Gomes, S. M. Monteiro, C. Venâncio, and L. Félix, “Protective Effects of 24-epibrassinolide Against the 6-OHDA Zebrafish Model of Parkinson's Disease,” Comparative Biochemistry and Physiology. Toxicology & Pharmacology: CBP 269 (2023): 109630.

[107] A. Nadig, B. Huwaimel, A. Alobaida, et al., “Manganese Chloride (MnCl₂) Induced Novel Model of Parkinson's Disease in Adult Zebrafish; Involvement of Oxidative Stress, Neuroinflammation and Apoptosis Pathway,” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 155 (2022): 113697.

[108] A. L. C. de Andrade, R. P. F. Silva, P. R. L. Soares, et al., “Evaluation of Toxicity and Non-Motor Symptoms of Parkinson-Like Induced by Rotenone in Zebrafish Animal Model,” preprint, January 9, 2023, https://doi.org/10.21203/RS.3.RS-2440652/V1.

[109] N. H. Mohamad Najib, M. F. Yahaya, S. Das, and S. L. Teoh, “The Effects of Metallothionein in Paraquat-Induced Parkinson Disease Model of Zebrafish,” International Journal of Neuroscience 133 (2023): 822–833.

[110] Y. Ihara, “Significance of Neurofibrillary Tangles in Alzheimer's Disease—Lessons from Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17,” in Mapping the Progress of Alzheimer's and Parkinson's Disease, Vol. 51 (2002), 27–32, https://doi.org/10.1007/978-0-306-47593-1_5.

[111] L. G. Apostolova and J. L. Cummings, “The Pathogenesis of Alzheimer's Disease: General Overview,” Protein Misfolding, Aggregation, and Conformational Diseases 6 (2007): 3–29, https://doi.org/10.1007/978-0-387-36534-3_1.

[112] C. A. Rankin, Q. Sun, and T. C. Gamblin, “Tau Phosphorylation by GSK-3ß Promotes Tangle-Like Filament Morphology,” Molecular Neurodegeneration 2 (2007): 12.

[113] T. Kiyota, “Animal Models of Alzheimer's Disease,” in Current Laboratory Methods in Neuroscience Research. Springer Protocols Handbooks, eds. H. Xiong and H. E. Gendelman (Springer, 2014), https://doi.org/10.1007/978-1-4614-8794-4_35.

[114] K. Schwarze-Eicker, K. Keyvani, N. Görtz, D. Westaway, N. Sachser, and W. Paulus, “Prion Protein (PrPc) Promotes β-Amyloid Plaque Formation,” Neurobiology of Aging 26 (2005): 1177–1182.

[115] L. M. Stevens and R. E. Brown, “Reference and Working Memory Deficits in the 3xTg-AD Mouse Between 2 and 15-Months of Age: A Cross-Sectional Study,” Behavioural Brain Research 278 (2015): 496–505.

[116] A. H. S. Harris, S. Gupta, T. Bowe, et al., “Predictive Validity of Two Process-of-Care Quality Measures for Residential Substance Use Disorder Treatment,” Addiction Science & Clinical Practice 10 (2015): 22.

[117] P. J. Bushnell, R. J. Kavlock, K. M. Crofton, B. Weiss, and D. C. Rice, “Behavioral Toxicology in the 21st Century: Challenges and Opportunities for Behavioral Scientists,” Neurotoxicology and Teratology 32 (2010): 313–328.

[118] N. Braidy, A. Poljak, T. Jayasena, H. Mansour, N. C. Inestrosa, and P. S. Sachdev, “Accelerating Alzheimer's Research Through ‘Natural’ Animal Models,” Current Opinion in Psychiatry 28 (2015): 155–164.

[119] M. Gallo, N. Marcello, S. A. Curcio, et al., “A Novel Pathogenic PSEN1 Mutation in a Family With Alzheimer's Disease: Phenotypical and Neuropathological Features,” Journal of Alzheimer's disease: JAD 25 (2011): 425–431, https://doi.org/10.3233/JAD-2011-110185.

[120] C. Behl and Y. Sagara, “Mechanism of Amyloid β Protein Induced Neuronal Cell Death: Current Concepts and Future Perspectives,” Journal of Neural Transmission, Supplement 6 (1997): 125–134, https://doi.org/10.1007/978-3-7091-6844-8_14.

[121] A. P. R. Nadiga, Suman, and K. L. Krishna, “A Novel Zebrafish Model of Alzheimer's Disease by Aluminium Chloride; Involving Nitro-Oxidative Stress, Neuroinflammation and Cholinergic Pathway,” European Journal of Pharmacology 965 (2024): 176332.

[122] M. Lardelli, L. Baer, N. Hin, A. Allen, S. M. Pederson, and K. Barthelson, “The Use of Zebrafish in Transcriptome Analysis of the Early Effects of Mutations Causing Early Onset Familial Alzheimer's Disease and Other Inherited Neurodegenerative Conditions,” Journal of Alzheimer's Disease 99 (2024): S367–S381.

[123] C. Barbereau, N. Cubedo, T. Maurice, and M. Rossel, “Zebrafish Models to Study New Pathways in Tauopathies,” International Journal of Molecular Sciences 22 (2021): 4626.

[124] R. Jarosova, S. S. Niyangoda, P. Hettiarachchi, and M. A. Johnson, “Impaired Dopamine Release and Latent Learning in Alzheimer's Disease Model Zebrafish,” ACS Chemical Neuroscience 13 (2022): 2924–2931.

[125] R. Gerlai, “Using Zebrafish to Unravel the Genetics of Complex Brain Disorders,” Current Topics in Behavioral Neurosciences 12 (2011): 3–24.

[126] J. Lachowicz, K. Niedziałek, E. Rostkowska, et al., “Zebrafish as an Animal Model for Testing Agents With Antidepressant Potential,” Life 11 (2021): 792.

[127] R. War, S. V, S. Paul, U. R. Sharma, S. J, and M. Pm, “Zebrafish as an Emerging Alternative Tool for Studying Anxiety Disorders,” Journal of Advanced Scientific Research 13 (2022): 13–20.

[128] A. V. Kalueff, et al., “Translational Neurobiology of Zebrafish (Danio rerio),” Genes & Cells 18 (2023): 480–482.

[129] D. S. Galstyan, T. O. Kolesnikova, Y. M. Kositsyn, et al., “Modeling Depression in Zebrafish,” Reviews on Clinical Pharmacology and Drug Therapy 20 (2022): 149–156.

[130] J. Näslund, J. Landin, F. Hieronymus, R. K. Banote, and P. Kettunen, “Anxiolytic-Like Effects of Acute Serotonin-Releasing Agents in Zebrafish Models of Anxiety: Experimental Study and Systematic Review,” Acta Neuropsychiatrica 37 (2025): e35.

[131] A. Tayanloo-Beik, S. K. Hamidpour, M. Abedi, et al., “Zebrafish Modeling of Autism Spectrum Disorders, Current Status and Future Prospective,” Frontiers in Psychiatry 13 (2022): 911770.

[132] D. Camussi, V. Naef, L. Brogi, et al., “Delving into the Complexity of Valproate-Induced Autism Spectrum Disorder: The Use of Zebrafish Models,” Cells 13 (2024): 1349.

[133] D. Camussi, M. Marchese, F. Nicoletti, F. M. Santorelli, and A. Ogi, “Valproate-Induced Model of Autism in Adult Zebrafish: A Systematic Review,” Cells 14 (2025): 109.

[134] J. Wu, X. Lin, D. Wu, et al., “Poly(I:C)-Exposed Zebrafish Shows Autism-Like Behaviors Which Are Ameliorated by fabp2 Gene Knockout,” Frontiers in Molecular Neuroscience 15 (2023): 1068019.

[135] E. Dreosti, E. J. Hoffman, and J. Rihel, “Modeling Autism Spectrum Disorders in Zebrafish,” Behavioral and Neural Genetics of Zebrafish 100 (2020): 451–480, https://doi.org/10.1016/B978-0-12-817528-6.00026-7.

[136] A. I. S. Andersen-Civil, R. A. Sawale, and G. C. Vanwalleghem, “Zebrafish (Danio rerio) as a Translational Model for Neuro-Immune Interactions in the Enteric Nervous System in Autism Spectrum Disorders,” Brain, Behavior, and Immunity 112 (2023): 254–266.

[137] G. Dougnon and H. Matsui, “Modelling Autism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) Using Mice and Zebrafish,” International Journal of Molecular Sciences 23 (2022): 7550.

[138] V. Rea and T. J. Van Raay, “Using Zebrafish to Model Autism Spectrum Disorder: A Comparison of ASD Risk Genes Between Zebrafish and Their Mammalian Counterparts,” Frontiers in Molecular Neuroscience 13 (2020): 575575.

[139] M. Hibi, K. Matsuda, M. Takeuchi, T. Shimizu, and Y. Murakami, “Evolutionary Mechanisms That Generate Morphology and Neural-Circuit Diversity of the Cerebellum,” Development, Growth & Differentiation 59 (2017): 228–243.

[140] W. H. J. Norton, “Toward Developmental Models of Psychiatric Disorders in Zebrafish,” Frontiers in Neural Circuits 7 (2013): 45315.

[141] S. Dey, T. Thamaraikani, and C. Vellapandian, “Advancing Alzheimer's Research With Zebrafish Models: Current Insights, Addressing Challenges, and Charting Future Courses,” Cureus 16 (2024), https://doi.org/10.7759/cureus.66935.

[142] A. Imeh-Nathaniel, et al., “A Critical Review of Zebrafish Neurological Disease Models−1. The Premise: Neuroanatomical, Cellular and Genetic Homology and Experimental Tractability,” Oxford Open Neuroscience 2 (2023), https://doi.org/10.1093/oons/kvac018.

[143] W. A. Sassen and R. W. Köster, “A Molecular Toolbox for Genetic Manipulation of Zebrafish,” Advances in Genomics and Genetics 5 (2015): 151–163.

[144] J. M. Doyle and R. P. Croll, “A Critical Review of Zebrafish Models of Parkinson's Disease,” Frontiers in Pharmacology 13 (2022), https://doi.org/10.3389/fphar.2022.835827.

[145] A. Shenoy, M. Banerjee, A. Upadhya, S. Bagwe-Parab, and G. Kaur, “The Brilliance of the Zebrafish Model: Perception on Behavior and Alzheimer's Disease,” Frontiers in Behavioral Neuroscience 16 (2022): 861155.

[146] E. M. S. Collins, E. V. S. Hessel, and S. Hughes, “How Neurobehavior and Brain Development in Alternative Whole-Organism Models Can Contribute to Prediction of Developmental Neurotoxicity,” Neurotoxicology 102 (2024): 48–57.

[147] C. Ramirez-Vizcarrondo, M. Hasan, J. Gu, A. Khakhalin, and C. Aizenman, “Novel Behavioral Assays to Model Neurodevelopmental Disorders in the Xenopus laevis Tadpole,” FASEB Journal 29, no. 1 (2015): 657.

[148] S. Ali, D. L. Champagne, and M. K. Richardson, “Behavioral Profiling of Zebrafish Embryos Exposed to a Panel of 60 Water-Soluble Compounds,” Behavioural Brain Research 228 (2012): 272–283.

[149] A. Santos-Fandila, E. Vázquez, A. Barranco, et al., “Analysis of 17 Neurotransmitters, Metabolites and Precursors in Zebrafish Through the Life Cycle Using Ultrahigh Performance Liquid Chromatography–Tandem Mass Spectrometry,” Journal of Chromatography B 1001 (2015): 191–201.

[150] E. P. Rico, D. B. Rosemberg, K. J. Seibt, K. M. Capiotti, R. S. Da Silva, and C. D. Bonan, “Zebrafish Neurotransmitter Systems as Potential Pharmacological and Toxicological Targets,” Neurotoxicology and Teratology 33 (2011): 608–617.

[151] J. P. Bourdineaud, R. Rossignol, and D. Brèthes, “Zebrafish: A Model Animal for Analyzing the Impact of Environmental Pollutants on Muscle and Brain Mitochondrial Bioenergetics,” International Journal of Biochemistry & Cell Biology 45 (2013): 16–22.

[152] A. Hagenaars, L. Vergauwen, D. Benoot, K. Laukens, and D. Knapen, “Mechanistic Toxicity Study of Perfluorooctanoic Acid in Zebrafish Suggests Mitochondrial Dysfunction to Play a Key Role in PFOA Toxicity,” Chemosphere 91 (2013): 844–856.

[153] G. Arveladze, N. Geladze, N. Khachapuridze, S. Bakhtadze, and N. Kapanadze, “Mitochondrial Dysfunction: Modern Aspects of Therapy (Review)],” Georgian Med News (2015): 78–84.

[154] J. F. Amatruda, J. L. Shepard, H. M. Stern, and L. I. Zon, “Zebrafish as a Cancer Model System,” Cancer Cell 1 (2002): 229–231.

[155] K. Kawakami, H. Takeda, N. Kawakami, M. Kobayashi, N. Matsuda, and M. Mishina, “A Transposon-Mediated Gene Trap Approach Identifies Developmentally Regulated Genes in Zebrafish,” Developmental Cell 7 (2004): 133–144.

[156] K. Chia, J. Mazzolini, M. Mione, and D. Sieger, “Tumor Initiating Cells Induce Cxcr4-Mediated Infiltration of Pro-Tumoral Macrophages Into the Brain,” Elife 7 (2018): e31918.

[157] S. W. Leacock, A. N. Basse, G. L. Chandler, A. M. Kirk, D. Rakheja, and J. F. Amatruda, “A Zebrafish Transgenic Model of Ewing's Sarcoma Reveals Conserved Mediators of EWS-FLI1 Tumorigenesis,” Disease Models & Mechanisms 5 (2012): 95–106.

[158] A. T. Nguyen, A. Emelyanov, C. H. V. Koh, J. M. Spitsbergen, S. Parinov, and Z. Gong, “An Inducible krasV12 Transgenic Zebrafish Model for Liver Tumorigenesis and Chemical Drug Screening,” Disease Models & Mechanisms 5 (2012): 63–72.

[159] Z. Li, W. Zheng, Z. Wang, et al., “A Transgenic Zebrafish Liver Tumor Model With Inducible Myc Expression Reveals Conserved Myc Signatures With Mammalian Liver Tumors,” Disease Models & Mechanisms 6 (2013): 414–423.

[160] C. Santoriello, E. Gennaro, V. Anelli, et al., “Kita Driven Expression of Oncogenic HRAS Leads to Early Onset and Highly Penetrant Melanoma in Zebrafish,” PLoS One 5 (2010): e15170.

[161] S. J. Callahan, S. Tepan, Y. M. Zhang, et al., “Cancer Modeling by Transgene Electroporation in Adult Zebrafish (TEAZ),” Disease Models & Mechanisms 11 (2018): dmm034561.

[162] S. Stella and G. Montoya, “The Genome Editing Revolution: A CRISPR-Cas TALE Off-Target Story,” BioEssays 38 (2016): S4–S13.

[163] J. D. Sander, L. Cade, C. Khayter, et al., “Targeted Gene Disruption in Somatic Zebrafish Cells Using Engineered TALENs,” Nature Biotechnology 29 (2011): 697–698.

[164] R. M. Gupta and K. Musunuru, “Expanding the Genetic Editing Tool Kit: ZFNs, Talens, and CRISPR-Cas9,” Journal of Clinical Investigation 124 (2014): 4154–4161.

[165] K. Stoletov, V. Montel, R. D. Lester, S. L. Gonias, and R. Klemke, “High-Resolution Imaging of the Dynamic Tumor Cell–Vascular Interface in Transparent Zebrafish,” Proceedings of the National Academy of Sciences of the United States of America 104 (2007): 17406–17411.

[166] D. M. Langenau, A. A. Ferrando, D. Traver, et al., “In Vivo Tracking of T Cell Development, Ablation, and Engraftment in Transgenic Zebrafish,” Proceedings of the National Academy of Sciences of the United States of America 101 (2004): 7369–7374.

[167] I. Mizgirev and S. Revskoy, “Generation of Clonal Zebrafish Lines and Transplantable Hepatic Tumors,” Nature Protocols 5 (2010): 383–394.

[168] Q. Tang, N. S. Abdelfattah, J. S. Blackburn, et al., “Optimized Cell Transplantation Using Adult rag2 Mutant Zebrafish,” Nature Methods 11 (2014): 821–824.

[169] M. S. Ignatius and D. M. Langenau, “Chapter 19-Fluorescent Imaging of Cancer in Zebrafish,” in Methods in Cell Biology, Vol. 105, eds. H. W. Detrich, M. Westerfield, and L. I. Zon (Academic Press, 2011), 437–459.

[170] C. Tulotta, C. Stefanescu, E. Beletkaia, et al., “Inhibition of Signaling Between Human CXCR4 and Zebrafish Ligands by the Small Molecule IT1t Impairs the Formation of Triple-Negative Breast Cancer Early Metastases in a Zebrafish Xenograft Model,” Disease Models & Mechanisms 9 (2016): 141–153.

[171] L. M. J. Lee, E. A. Seftor, G. Bonde, R. A. Cornell, and M. J. C. Hendrix, “The Fate of Human Malignant Melanoma Cells Transplanted Into Zebrafish Embryos: Assessment of Migration and Cell Division in the Absence of Tumor Formation,” Developmental Dynamics 233 (2005): 1560–1570.

[172] J. Ren, S. Liu, C. Cui, and P. Ten Dijke, “Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish,” Journal of Visualized Experiments 2017 (2017), https://doi.org/10.3791/55459.

[173] C. Zhao, H. Yang, H. Shi, et al., “Distinct Contributions of Angiogenesis and Vascular Co-Option During the Initiation of Primary Microtumors and Micrometastases,” Carcinogenesis 32 (2011): 1143–1150.

[174] G. Gaudenzi, M. Albertelli, A. Dicitore, et al., “Patient-Derived Xenograft in Zebrafish Embryos: A New Platform for Translational Research in Neuroendocrine Tumors,” Endocrine 57 (2017): 214–219.

[175] C. Yan, D. C. Brunson, Q. Tang, et al., “Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish,” Cell 177 (2019): 1903–1914.e14.

[176] W. Goessling, T. E. North, and L. I. Zon, “Ultrasound Biomicroscopy Permits In Vivo Characterization of Zebrafish Liver Tumors,” Nature Methods 4 (2007): 551–553.

[177] A. Canedo, P. Saiki, A. L. Santos, et al., “Zebrafish (Danio rerio) Meets Bioethics: The 10Rs Ethical Principles in Research,” Ciência Animal Brasileira 23 (2022): e-70884.

[178] L. Di Salvo, The Ethical and Moral Status of Invasive Animal Research: The Dilemma and Alternative Approaches (2017), https://doi.org/10.1002/hast.99.

[179] A. K. Kiani, et al., “Ethical Considerations Regarding Animal Experimentation,” Journal of Preventive Medicine and Hygiene 63 (2022): E255–E255.

[180] P. Delahaye, “A Semiotic Methodology for Animal Studies,” 19 (2019), https://doi.org/10.1007/978-3-030-28813-6.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).